Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors

BACKGROUND: Anti‐cancer drugs are approved typically on the basis of efficacy and safety as evaluated in phase III randomized trials (RCTs). Health‐related quality of life (HRQoL) is a direct measure of patient benefit, but is under‐reported. Here we explore associations with reporting of HRQoL data...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Ramy R., Meti, Nicholas, Ribnikar, Domen, Goldvaser, Hadar, Ocana, Alberto, Templeton, Arnoud J., Seruga, Bostjan, Amir, Eitan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643655/
https://www.ncbi.nlm.nih.gov/pubmed/32886422
http://dx.doi.org/10.1002/cam4.3390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643655/
https://www.ncbi.nlm.nih.gov/pubmed/32886422
http://dx.doi.org/10.1002/cam4.3390

Ejemplares similares